Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Michael L Demas"'
BACKGROUND Major depressive disorder (MDD) is the second highest cause of disability worldwide. Standard treatments for MDD include medicine and talk therapy; however, approximately 1 in 5 Canadians fail to respond to these approaches and must consid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::79fcccdad33eb861aab9be0bdf7fbaad
https://doi.org/10.2196/preprints.22805
https://doi.org/10.2196/preprints.22805
Autor:
Michael L Demas
Publikováno v:
The journal of ECT. 36(4)
Autor:
Mary-Anne B. MacKay, Jennifer Swainson, Carson Chrenek, Serdar M. Dursun, Rejish K. Thomas, Michael L Demas, Pratap Chokka, Shaina Archer, Larry J. Klassen, Glen B. Baker
Publikováno v:
Expert review of neurotherapeutics. 19(10)
Introduction: Treatment Resistant Depression (TRD) is a common and burdensome condition with poor outcomes and few treatment options. Esketamine is the S-enantiomer of ketamine and has recently been FDA approved in the United States for treating depr
Publikováno v:
JMIR Research Protocols
JMIR Research Protocols, Vol 10, Iss 3, p e22805 (2021)
JMIR Research Protocols, Vol 10, Iss 3, p e22805 (2021)
Background Major depressive disorder (MDD) is the second highest cause of disability worldwide. Standard treatments for MDD include medicine and talk therapy; however, approximately 1 in 5 Canadians fail to respond to these approaches and must consid